# Medical Writing Skill

Comprehensive patterns for clinical, regulatory, and patient-facing medical writing following industry standards.

## Clinical Trial Protocol Structure (SPIRIT Guidelines)

### Protocol Sections
1. **Title and Trial Registration**
   - Descriptive title with intervention, population, comparator
   - Trial registration number (ClinicalTrials.gov)
   - Protocol version and date

2. **Abstract/Summary**
   - Background, objectives, design, participants, interventions, outcomes
   - 250-300 words maximum

3. **Introduction**
   - Background and rationale
   - Review of existing evidence
   - Justification for trial
   - Research hypothesis

4. **Objectives and Endpoints**
   - Primary objective (single, focused)
   - Secondary objectives
   - Primary endpoint (single, pre-specified)
   - Secondary endpoints
   - Exploratory endpoints

5. **Trial Design**
   - Study type (interventional, observational)
   - Allocation (randomized, non-randomized)
   - Blinding (open-label, single-blind, double-blind)
   - Control type (placebo, active, no intervention)
   - Parallel, crossover, or factorial design

6. **Methods: Participants**
   - Inclusion criteria (specific, measurable)
   - Exclusion criteria (safety-focused)
   - Recruitment setting and strategy
   - Study timeline

7. **Methods: Interventions**
   - Detailed intervention description
   - Dosing regimen and administration
   - Adherence monitoring
   - Concomitant medications
   - Rescue medications

8. **Methods: Outcomes**
   - Primary outcome definition and timing
   - Secondary outcomes with timing
   - Assessment methods and tools
   - Validated instruments

9. **Methods: Sample Size**
   - Primary outcome basis
   - Effect size and assumptions
   - Power and alpha levels
   - Dropout rate
   - Total sample needed

10. **Methods: Statistical Analysis**
    - Primary analysis approach
    - Analysis populations (ITT, PP, Safety)
    - Handling of missing data
    - Interim analyses
    - Stopping rules
    - Subgroup analyses

11. **Methods: Monitoring**
    - Data Monitoring Committee (DMC)
    - Safety monitoring plan
    - Auditing procedures

12. **Ethics and Dissemination**
    - IRB/Ethics committee approval
    - Informed consent process
    - Confidentiality measures
    - Dissemination plan
    - Data sharing statement

### SPIRIT Checklist
Must address all 33 items in SPIRIT 2013 Statement

## Medical Manuscript Structure (IMRAD Format)

### IMRAD Components

#### Introduction
- **Background**: Disease burden, current knowledge
- **Gap**: What's unknown
- **Objective**: Study aim (typically last sentence)
- **Length**: 3-4 paragraphs, 500-750 words

#### Methods
- **Study design**: Clearly state design type
- **Setting and participants**: Where, who, when
- **Interventions**: Detailed description
- **Outcomes**: Primary first, then secondary
- **Sample size**: Justification with power calculation
- **Randomization**: Method and allocation concealment
- **Blinding**: Who was blinded
- **Statistical analysis**: Tests used, software, significance level
- **Ethics**: IRB approval, registration number

#### Results
- **Order**: Follow objectives/endpoints order
- **Primary outcome first**: State clearly
- **Participant flow**: CONSORT diagram
- **Baseline characteristics**: Table 1
- **Primary results**: Text + table/figure
- **Secondary outcomes**: Each addressed
- **Adverse events**: Safety reporting
- **No interpretation**: Save for Discussion

#### Discussion
- **Structure**:
  1. Principal findings (1 paragraph)
  2. Strengths and limitations (1-2 paragraphs)
  3. Comparison with other studies (2-3 paragraphs)
  4. Meaning and implications (1-2 paragraphs)
  5. Unanswered questions and future research (1 paragraph)
- **Avoid**: Overstating findings, circular reasoning

### Journal Guidelines

#### High-Impact Journals (NEJM, Lancet, JAMA)
- Structured abstract (250-300 words)
- Word limit: 3000-4000 for main text
- Tables/figures: 4-6 maximum
- References: 30-40 maximum
- Clinical trial registration mandatory
- Data sharing statement required

#### Specialty Journals
- Check specific formatting requirements
- Adherence to reporting guidelines (CONSORT, STROBE, PRISMA)

## Patient Education Materials

### Plain Language Principles

#### Readability Standards
- **Target**: 6th-8th grade reading level
- **Tools**: Flesch-Kincaid, SMOG index
- **Goal**: Flesch Reading Ease score 60-70

#### Writing Techniques
- **Short sentences**: 15-20 words maximum
- **Simple words**: Everyday language, not medical jargon
- **Active voice**: "Take your medicine" not "Medicine should be taken"
- **Personal pronouns**: "You" and "your"
- **Concrete examples**: "Walk for 30 minutes" not "Increase physical activity"

#### Terminology
- **Medical terms**: Define on first use
- **Alternatives**:
  - Hypertension → high blood pressure
  - Myocardial infarction → heart attack
  - Cerebrovascular accident → stroke
  - Adverse event → side effect
  - Contraindication → reason not to use

#### Structure for Patient Materials

**Title**: Clear, specific benefit-focused
**Introduction**: What and why in 1-2 sentences
**Body**:
- Short paragraphs (3-4 sentences)
- Bulleted lists
- Headings every 2-3 paragraphs
- White space for readability

**Visual Aids**:
- Simple diagrams
- Step-by-step illustrations
- Pictures with labels
- Icons for emphasis

**Action Steps**:
- Numbered steps
- Checkboxes
- "What to do if..." sections

**Contact Information**:
- When to call doctor
- Emergency information
- Resources and support

### Health Literacy Considerations
- Test with target audience
- Use teach-back method
- Cultural sensitivity
- Numeracy issues (risk communication)
- Visual learners

## Regulatory Writing

### IND (Investigational New Drug) Application

#### Format
- **Form FDA 1571**: Cover sheet
- **Table of contents**: Comprehensive
- **Introductory statement**: Summary
- **General investigational plan**: Development strategy
- **Investigator's brochure**: Drug information
- **Protocols**: Clinical study protocols
- **Chemistry, Manufacturing, Controls (CMC)**: Drug substance and product
- **Pharmacology and Toxicology**: Preclinical studies
- **Previous human experience**: Prior clinical data
- **Additional information**: Supporting documents

#### Writing Standards
- **Clarity**: Unambiguous language
- **Precision**: Exact specifications
- **Completeness**: All required information
- **Consistency**: Terminology throughout
- **Traceability**: Cross-references and linkages

### NDA (New Drug Application)

#### CTD Format (Common Technical Document)

**Module 1: Administrative and Prescribing Information**
- Regional administrative information
- Prescribing information (label)

**Module 2: CTD Summaries**
- 2.3: Quality Overall Summary
- 2.4: Nonclinical Overview
- 2.5: Clinical Overview
- 2.6: Nonclinical Written and Tabulated Summaries
- 2.7: Clinical Summary

**Module 3: Quality**
- Drug substance and drug product information

**Module 4: Nonclinical Study Reports**
- Pharmacology, pharmacokinetics, toxicology

**Module 5: Clinical Study Reports**
- Study reports for all clinical trials

#### Key Documents

**Clinical Overview (2.5)**
- Product development rationale
- Overview of biopharmaceutics
- Overview of clinical pharmacology
- Overview of efficacy
- Overview of safety
- Benefit-risk assessment
- Literature references

**Clinical Summary (2.7)**
- Biopharmaceutics
- Clinical pharmacology
- Clinical efficacy
- Clinical safety
- Integration of benefit-risk

### FDA/EMA Requirements

#### FDA Expectations
- ICH guidelines compliance
- CDER/CBER guidance documents
- 21 CFR regulations
- Electronic submission format (eCTD)

#### EMA Expectations
- ICH guidelines
- EMA guidelines
- CHMP opinions
- National requirements

## Scientific Abstract Writing

### Conference Abstracts

#### Structured Format (250-300 words)
- **Background/Introduction** (2-3 sentences): Context and rationale
- **Objective/Aim** (1 sentence): Clear, specific aim
- **Methods** (3-4 sentences): Design, participants, interventions, outcomes
- **Results** (4-5 sentences): Primary outcome first, key findings with data
- **Conclusion** (2-3 sentences): Interpretation and implications

#### Unstructured Format (300-350 words)
- Same content, flowing paragraphs
- No section headers
- Smooth transitions

### Key Elements
- **Title**: Informative, specific, 15-20 words
- **Numbers**: Include key data points
- **Significance**: P-values, confidence intervals, effect sizes
- **Clarity**: Can stand alone without full paper
- **Keywords**: Include major concepts for indexing

## Medical Terminology and Style

### AMA Manual of Style (11th Edition)

#### Numbers
- **Spell out**: Zero through nine (except in data, measurements, age)
- **Numerals**: 10 and above
- **Units**: Space between number and unit (10 mg, 5 mL)
- **Percentages**: Use % symbol with number (25%, not 25 percent)
- **Ranges**: Use en dash (5-10 days, 20%-30%)

#### Abbreviations
- **Define on first use**: "myocardial infarction (MI)"
- **Standard abbreviations**: Do not define (DNA, RNA, HIV)
- **Latin abbreviations**: Use sparingly (eg, ie, vs, et al)
- **Units**: No periods (mg, mL, kg, not mg., mL., kg.)

#### Capitalization
- **Drug names**: Generic lowercase, trade names capitalized
- **Diseases**: Lowercase (diabetes, hypertension)
- **Eponyms**: Capitalize person's name (Alzheimer disease, Parkinson disease)
- **Tests**: Lowercase unless proper name (t test, Mann-Whitney test)

#### Formatting
- **Italics**: P values, statistical symbols (P = .04, r = 0.85, F = 3.2)
- **Statistical significance**: P < .05 or P = .04 (no leading zero if <1)
- **Precision**: Match to measurement precision (P = .04, not P = .042)

### APA Style (7th Edition)

#### In-Text Citations
- **(Author, Year)**: Smith (2020) or (Smith, 2020)
- **Two authors**: Smith and Jones (2020) or (Smith & Jones, 2020)
- **3+ authors**: Smith et al. (2020) or (Smith et al., 2020)

#### Reference List
- Hanging indent
- Alphabetical by first author surname
- Include DOI when available

**Journal Article**:
```
Author, A. A., Author, B. B., & Author, C. C. (Year). Title of article.
  Title of Journal, Volume(Issue), pages. https://doi.org/xxx
```

## Citation and Reference Styles

### Vancouver Style (Biomedical Journals)

#### In-Text Citations
- **Numbered**: Sequential order of appearance [1], [2], [3]
- **Multiple**: [1-3] or [1,3,5]
- **Same citation**: Use same number throughout

#### Reference List
1. Author AA, Author BB, Author CC. Title of article. Abbreviated Journal Name. Year;Volume(Issue):pages.

**Example**:
```
1. Smith J, Jones K, Brown L. Effects of drug X on hypertension.
   N Engl J Med. 2020;382(4):315-24.
```

#### Types of Sources

**Journal Article (3-6 authors)**:
```
1. Author AA, Author BB, Author CC, Author DD, Author EE, Author FF.
   Article title. J Abbrev. Year;Volume:pages.
```

**Journal Article (>6 authors)**:
```
1. Author AA, Author BB, Author CC, et al. Article title.
   J Abbrev. Year;Volume:pages.
```

**Book**:
```
1. Author AA. Book Title. Edition. Place: Publisher; Year.
```

**Book Chapter**:
```
1. Author AA. Chapter title. In: Editor BB, Editor CC, editors.
   Book Title. Place: Publisher; Year. p. pages.
```

**Website**:
```
1. Organization Name. Title of webpage [Internet]. Place: Publisher;
   Year [cited YYYY Mon DD]. Available from: URL
```

### Harvard Style (Social Sciences)

#### In-Text Citations
- **(Author Year)**: (Smith 2020) or Smith (2020)
- **Page numbers**: (Smith 2020, p. 15) for direct quotes

#### Reference List
- Alphabetical by surname
- Hanging indent

**Journal Article**:
```
Smith, J., Jones, K. and Brown, L. (2020) 'Title of article',
  Journal Name, 382(4), pp. 315-324. doi: 10.xxxx/xxxxx.
```

## Evidence-Based Writing

### Levels of Evidence

#### GRADE System
- **High**: Further research very unlikely to change confidence
- **Moderate**: Further research likely to impact confidence
- **Low**: Further research very likely to impact confidence
- **Very Low**: Any estimate very uncertain

#### Oxford CEBM Levels
- **Level 1**: Systematic reviews, RCTs
- **Level 2**: Cohort studies
- **Level 3**: Case-control studies
- **Level 4**: Case series
- **Level 5**: Expert opinion

### Strength of Recommendations
- **Strong**: "We recommend..."
- **Conditional**: "We suggest..."
- **Based on**: Evidence quality and balance of benefits/harms

### Critical Appraisal
- **Validity**: Bias minimized?
- **Results**: Effect size, precision, clinical significance
- **Applicability**: Relevant to target population?

## Good Clinical Practice (GCP) Documentation

### ICH-GCP Guidelines

#### Essential Documents
- **Before trial**: Protocol, consent forms, IRB approval, CVs
- **During trial**: Source documents, CRFs, monitoring logs, amendments
- **After trial**: Final report, audit certificate, retention records

#### Source Documentation
- **Attributable**: Who recorded it
- **Legible**: Clearly readable
- **Contemporaneous**: Recorded when occurred
- **Original**: First recording of data
- **Accurate**: Error-free
- **Complete**: All required data

#### Case Report Forms (CRF)
- Pre-specified data collection
- Clear instructions
- Space for corrections
- Sign-off requirements
- Query management

### Adverse Event Reporting

#### Documentation Requirements
- **Event description**: Medical terminology, severity
- **Onset and resolution**: Dates and times
- **Causality assessment**: Relationship to study drug
- **Action taken**: Dose modification, treatment, discontinuation
- **Outcome**: Recovered, ongoing, sequelae, death
- **Seriousness criteria**: Death, life-threatening, hospitalization, disability, congenital anomaly, medically important

#### Timelines
- **SAE reporting**: 24 hours to sponsor
- **SUSAR reporting**: 7 days (fatal/life-threatening), 15 days (others)
- **Annual safety reports**: Within 60 days of data lock

### Study Reports

#### ICH E3 Structure
1. **Title page**
2. **Synopsis** (2-3 pages)
3. **Table of contents**
4. **List of abbreviations**
5. **Ethics**
6. **Investigators**
7. **Introduction**
8. **Study objectives**
9. **Investigational plan**
10. **Study patients**
11. **Efficacy evaluation**
12. **Safety evaluation**
13. **Discussion and conclusions**
14. **Tables, figures, graphs**
15. **Reference list**
16. **Appendices**

---

## Quick Reference Tables

### Word Count Guidelines

| Document Type | Typical Length |
|---------------|----------------|
| Protocol | 30-60 pages |
| Informed consent | 5-15 pages |
| Clinical study report | 100-300 pages |
| Journal article | 3000-4000 words |
| Abstract | 250-350 words |
| Patient brochure | 500-1000 words |
| Regulatory summary | 10-50 pages |

### Timeline Standards

| Milestone | Timeline |
|-----------|----------|
| Protocol development | 4-8 weeks |
| IRB submission to approval | 4-6 weeks |
| Manuscript writing | 6-12 weeks |
| Journal peer review | 8-16 weeks |
| IND submission to feedback | 30 days (FDA) |
| NDA review | 10 months standard |

### Abbreviations Reference

| Abbreviation | Full Term |
|--------------|-----------|
| AE | Adverse Event |
| SAE | Serious Adverse Event |
| ITT | Intention to Treat |
| PP | Per Protocol |
| RCT | Randomized Controlled Trial |
| IRB | Institutional Review Board |
| ICF | Informed Consent Form |
| CRF | Case Report Form |
| DSMB | Data Safety Monitoring Board |
| GCP | Good Clinical Practice |
| ICH | International Council for Harmonisation |

---

**Version**: 1.0
**Last Updated**: January 2025
**Guidelines Referenced**: SPIRIT 2013, CONSORT 2010, ICH-GCP E6(R2), ICH E3, AMA 11th, APA 7th, GRADE
**Regulatory Standards**: FDA 21 CFR, EMA Guidelines, ICH CTD
